Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NxM CAR T cells
- Development stage
- Preclinical
- Lead developer
- Fate Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
NxM CAR T cells are a next-generation, off-the-shelf, multi-antigen targeting chimeric antigen receptor (CAR) T-cell platform developed by Fate Therapeutics for the treatment of autoimmune diseases. Derived from a clonal induced pluripotent stem cell (iPSC) line, these cells are engineered to eliminate diverse populations of aberrant B and T cells without the need for conditioning chemotherapy. The platform incorporates multiple synthetic elements, including CARs targeting CD19 (utilizing a 1XX signaling endodomain), BCMA, and/or CD38. To enhance persistence and function in an allogeneic setting without lymphodepletion, the cells are further modified with an Allo-immune Defense Receptor (ADR), genetic disruption of the immune synapse molecule CD58 (CD58 KO), and knockout of the endogenous T-cell receptor (TCR). This approach aims to provide a scalable, outpatient-compatible 'immunological reset' for patients with systemic lupus erythematosus (SLE) and other B- and T-cell driven pathologies.
- Other names
- next-generation multi-antigen targeting CAR T cells
02
Targets
CD19 (B lymphocyte antigen CD19)BCMA (B-cell maturation antigen)CD58 (Leukocyte function-associated antigen 3)TRAC (T cell receptor alpha variable 17)CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on NxM CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NxM CAR T cells.